BioInvent streamlines agreement on anti-FcγRllB antibody, BI-1206, ahead of Phase I/II data |
| January 11, 2021 | January 2021 Bond Updates |
|
LUND, Sweden, Jan. 11, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces it has restructured a clinical development agreement with Cancer Research UK (CRUK), the world's leading cancer charity, for its unique anti-FcγRIIB antibody,... |
| View more at: https://www.prnewswire.com:443/news-releases/bioinvent-streamlines-agreement-on-anti-fcrllb-antibody-bi-1206-ahead-of-phase-iii-data-301204962.html |
| Related News |
|